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Efficacy of paclitaxel in cancer patients has been hampered by the
ability of cells to develop paclitaxel resistance (Rowinsky et al,
1992; Rowinsky and Donehower, 1995). Therefore if we under-
stand the mechanism of paclitaxel resistance we will be more
successful in the treatment of human cancer. It has been shown
that several factors contribute to paclitaxel resistance in vitro:
1. P-glycoprotein (P-gp), an energy-dependent drug efflux pump
shown to confer multidrug resistance (MDR) (Gottesman and
Pastan, 1988, 1993; Lehnert, 1996; Germann, 1996)
2. alterations in b-tubulin isotypes (Haber et al, 1995;
Ranganathan et al, 1988, 1996, 1998 Kavallaris et al, 1997,
1999)
3. mutations in tubulins (Cabral et al, 1981; Schibler and Cabral,
1986; Giannakakou et al, 1997)
4. up-regulation of caveolin-1 (Yang et al, 1998).
Paclitaxel also activates molecules that are involved in signal
transduction pathways such as c-jun N-terminal kinase
(Blagosklonny et al, 1995; Wolfson et al, 1997; Wang et al, 1998).
Annexins are a family of calcium-dependent phospholipid
binding proteins. There are at least 13 annexin family members
with a similar structure, characterized by the presence of four or
eight repeats of a 70 amino acid motif and a variable N-terminal
end (Smith and Moss, 1994; Dubois et al, 1996; Benz-and
Hofmann, 1997). Although the roles of the annexins are not well
understood, they have been involved in various biological
processes including inhibition of phospholipase A2, anticoagula-
tion, endocytosis, exocytosis, inhibition of calcium channels and
protein kinase C activity (Smith and Moss, 1994). It was also previ-
ously shown that annexin II was elevated in doxorubicin-resistant
small-cell lung cancer cell line (Cole et al, 1992). During the course
of our antimitotic research, we found that annexin IV was overex-
pressed in A204197-resistant human colon cancer HCT-15 cells as
determined by two-dimensional protein mapping as well as mass
spectroscopic analysis. Therefore, we tested whether annexin IV or
annexin II was also overexpressed in a paclitaxel-resistant cell line,
H460/T800. To our surprise annexin IV, but not annexin II, was
overexpressed in the paclitaxel-resistant H460 lung cancer cell line.
To further confirm the role of annexin IV in drug resistance,
annexin IV cDNA was transfected into 293T cells. Annexin IV
transfectants were more resistant to paclitaxel as compared to the
vector controls. Thus our study indicates that annexin IV plays a
role in regulating paclitaxel resistance.
MATERIALS AND METHODS
Cell culture
Lung cancer cell line NCI-H460 (hereafter referred to as H460)
and colon cancer cell line HCT15 were obtained from the
American Tissue Culture Collection (ATCC) H460 and HCT15
cells were grown and maintained in RPMI medium plus 10% fetal
bovine serum (FBS) or 20% FBS respectively. Paclitaxel-resistant
cell lines were derived from the H460 parental cell line. H460 cells
were initially selected with IC50 concentration of paclitaxel and
thereafter paclitaxel concentration was doubled every 2–3 weeks
until 800 nM paclitaxel resistance was obtained. HCT15/A204197
cells were selected with an antimitotic compound, A204197 in
HCT15 parental cells. HCT15/A204197 cells were maintained in
200 nM A204197. Embryonic kidney 293T cells were maintained
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Paclitaxel and all other chemicals were obtained from Sigma
(St Louis, MO, USA). The discovery and characterization of
A204197 will be described elsewhere. Cell cultures were
maintained in a 37°C incubator with 5% carbon dioxide.
Two-dimensional gel electrophoresis
Two-dimensional gel electrophoresis was performed according to
the method of O’Farrell (1975) as follows: isoelectric focusing
(IEF) was carried out in glass tubes of inner diameter 2.0 mm
using 2% pH 4–8 ampholines (BDH from Hoefer Scientific
Instruments, San Francisco, CA, USA) for 9600 volts-hours. One
microgram of an IEF internal standard, tropomyosin, was added to
each sample. This protein migrates as a doublet with lower
polypeptide spot of MW 33 000 and pI 5.2; an arrowhead on the
stained gel marks its position. The enclosed tube gel pH gradient
plot for this set of ampholines was determined with a surface pH
electrode. After equilibration for 10 min in Buffer ‘O’ (10% glyc-
erol, 50 mM dithiothreitol (DTT), 2.3% sodium dodecyl sulphate
(SDS) and 0.0625 M Tris, pH 6.8) the tube gels were sealed to the
top of stacking gels on top of 10% acrylamide slab gels (0.75-mm-
thick) and SDS slab gel electrophoresis carried out for about 4 h at
12.5 mA/gel. The following proteins (Sigma Chemicals Co., St
Louis, MO, USA) were added as MW standards to a well in the
arose which sealed the tube gel to the slab gel: myosin (220 000),
phosphorylase A (94 000), catalase (60 000), actin (43 000),
carbonic anhydrase (29 000) and lysozyme (14 000). These stan-
dards appear as horizontal lines on the Coomassie brilliant blue 
R-250 stained 10% acrylamide slab gels. The silver-stained gels
were dried between sheets of cellophane with the acid edge to the
left. After slab gel electrophoresis, duplicate gels were transferred
to transfer buffer (12.5 mM Tris, pH 8.8, 86 mM glycine, 10%
methanol) transblotted onto polyvinylidene fluoride (PVDF)
membrane overnight at 200 mA and approximately 100 volts/two
gels. The spot was removed and mass spectroscopic analysis was
performed.
Protein extraction and Western blot analysis
Protein extracts were prepared from exponentially growing cells
as described (Han et al, 1995, 1996). Briefly, cells were collected
and the cell pellets were resuspended in lysis buffer (20 mM
Tris–HCl pH 7.4, 2 mM EGTA, 2 mM EDTA, 6 mM b-mercapto-
ethanol, 1% NP-40, 0.1% SDS and 10 mM sodium fluoride, plus
the protease inhibitors aprotinin (10 mg ml–1), leupeptin (10 mg
ml–1) and phenylmethylsulphonyl fluoride (PMSF, 1 mM)). This
suspension was sonicated three times with a Sonifier Cell
Disrupter (Branson Ultrsonics Co, Danbury, CT, USA). Cells were
spun briefly and supernatants were collected for determination of
protein concentration by the Bio-Rad assay (Bio-Rad, San Diego,
CA, USA). For Western blotting, 20 mg of protein from the total
cell lysates were fractionated by SDS polyacrylamide gel elec-
trophoresis (SDS-PAGE). The proteins on these gels were then
transferred to immobilon-P membranes (Millipore, Bedford, MA,
USA), using transfer buffer (25 mM Tris, 190-mM glycine, 10%
methanol). Membranes were blocked with blocking buffer (50 mM
Tris, 200 mM sodium chloride, 0.2% Tween-20, 3% non-fat dry
milk), and the membranes were then incubated with the indicated
antibodies. Human annexin IV and annexin II (1:1000,
Transduction Laboratories, Lexington, KY, USA) antibodies were
used. After treatment with blocking buffer without 3% non-fat dry
milk (washing buffer), a dilute solution (1:2000) of horseradish
peroxidase linked anti-rabbit donkey serum (Amersham,
Arlington Heights, IL, USA) was added. Membranes were then
washed with washing buffer and immune detection was performed
using the enhanced chemiluminescence (ECL) Western blotting
detection system (Amersham, Arlington Heights, IL, USA).
Immunohistochemistry
The medium was aspirated off and the cells were fixed in 10%
formalin in phosphate-buffered saline (PBS) for 30 min at room
temperature. Cells were washed once in PBS and incubated in
blocking buffer (2% bovine serum albumin (BSA), 0.2% non-fat
dry milk, 0.4% Triton X-100 in PBS) for 1 h at room temperature.
The blocking buffer was aspirated off and the cells were incubated
with either a mouse anti-annexin II or annexin IV IgG (diluted
1:4000 in block buffer) for 1 h at 37°C. The cells were washed
3 ´ for 5 min each time in was buffer (0.2% Tween-20 in PBS)
and incubated with a goat anti-mouse Alexa 488 conjugated IgG
(diluted 1:1000 in block buffer) for 0.5 h at 37°C. The cells were
washed 3 ´ for 5 min each time in wash buffer, wet mounted
with Citifluor and imaged with a BioRad MRC-1000 confocal
microscope using a 60´ objective.
Determination of IC50
Cytotoxicity assays were performed in 96-well microtitier plates
using the colourimetric method as described (Skehan et al, 1990).
To measure cell proliferation, the sulphorhodamine binding assay
(SRB) was performed in the presence of paclitaxel, colchicine, or
nocodazole (10–1 to 10–11M) in 96-well plates containing cells at
60–70% confluency. Cells were cultured in the presence of
above drugs for 48 h, after which time they were fixed with 10%
trichloroacetic acid, stained with 0.4% SRB in 1% acetic acid,
washed and dried. The remaining dye was solubilized in Tris
buffers, and the plates were read at O.D. 490 nM for quantification.
All IC50 values are a representation of 2–3 independent
experiments.
Annexin IV cDNA transfection
Annexin IV cDNA was purchased from the ATCC
(ATCC#525860, Rockville, MD, USA). The insert (~1.5 kb,
EcoRI/Not fragment) was subcloned into a pcDNA 3.1 (+) expres-
sion vector (Invitrogen, Carlsbad, CA, USA) in the sense orienta-
tion. After subcloning into the pcDNA vector, a large-scale
preparation was performed using Qiagen plasmid purification kit
(Qiagen, Chatsworth, CA, USA). Transfection into 293 T-cells
was performed using Lipofectamine Plus kit (Gibco-BRL, Grand
Island, NY, USA). After transfection, cells were selected in the
presence of 1 mg ml–1 G418, colonies were isolated and expanded.
RESULTS
Two-dimensional gel mapping analysis of
HCT15/A204197 cells
A204197 is a novel antimitotic compound that binds to the
colchicine-binding site on tubulin (data to be published else-
where). To understand the mechanism of A204197 resistance, we
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concentration of A204197. A204197-resistant HCT15 cells (desig-
nated as HCT15/A204197) were maintained in 200 nM A204197
and displayed a 4.2-fold increase in resistance to A204197 when
compared to the parental HCT15 cells. The IC50 value increased
from 40.8 nM to 172 nM. HCT15/A204197 cells also showed slight
increase in resistance to other antimitotic compounds such as
paclitaxel, colcemid or nocodazole (data not shown). To examine
if any proteins are overexpressed or altered in HCT15/A204197
cells, we performed two-dimensional gel mapping analysis. As
shown in Figure 1A, there was one spot (calculated MW ~30 kDa,
pI ~6.0) which was overexpressed in HCT15/A204197 cells.
Computer analysis of the two-dimensional gel showed that this
was the most distinct spot to be overexpressed in A204197 resis-
tant HCT15 cells. This spot was cut out and mass spectroscopic
analysis was done following trypsin digestion. Partial protein
sequence determination of trypsin digested fragments revealed that
the unknown protein was annexin IV. To further confirm that the
annexin IV protein is overexpressed in HCT15/A204197 cells,
Western blot analysis was performed in HCT15/A204197 cells. As
shown in Figure 1B, annexin IV protein was overexpressed in
HCT15/A204197 cells by approximately twofold. Since we know
more about paclitaxel-resistant H460 cells and given paclitaxel’s
importance as a clinical anticancer therapeutic, we decided to
focus on these cells for our annexin IV study.
Annexin IV overexpression in paclitaxel-resistant H460
cell line
It was previously shown that annexin II expression was elevated in
doxorubicin selected MDR small-cell lung cancer cell line (Cole et
al, 1992). We further examined whether annexin II or annexin IV
was overexpressed in paclitaxel-resistant variants derived from
H460 cells. Previously we developed a series of paclitaxel-resis-
tant cell lines from H460 lung cancer cells to study the mechanism
of paxlitaxel resistance. For example, the H460/T800 cell line was
maintained at 800 nM paclitaxel and was over 1000-fold resistant
to paclitaxel. This cell line overexpresses P-gp and exhibits cross-
resistance to other MDR compounds (characterization of pacli-
taxel-resistant H460 cell lines will be published elsewhere). Cell
extracts from each selection step (T100, T200, T400, T800; T
stands for paclitaxel and each number represents nM concentration
of paclitaxel maintained in the medium) were analysed for annexin
II and annexin IV expression by Western blot analysis. As shown
in Figure 2A, as cells became more resistant to paclitaxel there was
a corresponding increase in expression of annexin IV protein.
Overexpression of annexin IV contributes to paclitaxel resistance 85
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Figure 1 (A) Two-dimensional gel mapping of HCT15 and HCT15/A204197 cells. Acidic proteins are oriented to the left, basic to the right, low molecular
weight proteins toward the bottom (MW in kilodaltons), and high MW proteins toward the top. The horizontal dimension represents a pH gradient of 4–8. The
arrowhead indicates the internal standard, tropomyosin (MW 33 kDa, pI = 5.2). Annexin IV protein (calculated pI = 6.4, MW = 30 kDa) was indicated by circle in
HCT15/A204197 cells. (B) Western blot analysis of annexin IV in HCT15 and HCT15/A204197. For details see Materials and MethodsHowever, annexin II protein expression was not altered in pacli-
taxel-resistant cell lines.
To further confirm and localize the expression of annexin IV
and II in H460/T800 cells, we performed immnohistochemistry
using either annexin IV or annexin II antibody. As shown in Figure
2B, there was an intense staining of annexin IV in the nucleus of
H460/T800 cells. In addition a diffuse staining of annexin IV was
observed in the cytosol of H460/T800 cells. In contrast, a diffused
annexin IV staining was seen in both the cytosol and nucleus in
H460 parental cells. There was no difference in annexin II staining
in either control H460 or H460/T800 cells. Annexin II staining
was localized to the membrane in both H460 and H460/T800 cells.
Short-term effects of paclitaxel on annexin IV
expression in H460/T800 cells
To examine whether short-term treatment with paclitaxel can
induce annexin IV protein expression, exponentially growing
H460 cells were treated with 10 nM paclitaxel and the expression
of annexin IV was determined over a 4-day period. As shown in
Figure 3A, there was a gradual increase in annexin IV protein
during the 4-day period. However, annexin II protein expression
was not affected during the same period.
We examined the change in annexin IV protein by immunohis-
tochemistry during the 4-day paclitaxel treatment in H460 cells.
As shown in Figure 3B, there was an increase in fluorescence
intensity of annexin IV in the nucleus in 10nM paclitaxel-treated
cells starting at day 1 and compared to the untreated controls. The
intensity was stronger at day 4. The increase in signal was not
homogeneous for the population as a whole. However, overall
annexin IV staining in paclitaxel-treated cells was much stronger
than the control cell line.
To determine whether annexin IV expression has any correla-
tion with paclitaxel resistance following 4-day paclitaxel treat-
ment, cells were analysed for cell proliferation in the presence of
increasing concentrations of paclitaxel. As shown in Figure 3C,
pretreatment with paclitaxel led to ~fivefold increase in the cell
proliferation IC50 when compared to the control cell line (27 nM
versus 5.2 nM respectively). During this time period, there was no
induction of P-gp or b-tubulin as determined by Western blot
analysis (data not shown).
Transfection of annexin IV cDNA into 293T cells
To further confirm that annexin IV is involved in paclitaxel
resistance, we transfected annexin IV cDNA into 293T cells.
Following transfection cells were selected with G418 (1 mg ml–1)
and a number of G418-resistant clones were obtained and
analysed. As shown in Figure 4A, two annexin IV clones (#9, #12)
overexpressed at least twofold more annexin IV protein than the
vector clones (Vt#15, Vt#18). Immunostaining study showed that
annexin IV clones display stronger nuclear staining for annexin IV
(data not shown). These clones were analysed for cell proliferation
in the presence of drugs using SRB assay. As shown in Figure 4B,
annexin IV clones displayed a ~threefold increase in the IC50
against paclitaxel. Similarly, there was a 1.5-fold increase in the
IC50 of annexin IV clones against colchicine or nocodazole when
compared to the vector control clones.
DISCUSSION
In this report, we have demonstrated that:
1. overexpression of annexin IV was identified in
HCT15/A204197 cells by two-dimensional gel protein
mapping, mass spectroscopy and confirmed by Western blot
analysis
2 overexpression of annexin IV was also seen in paclitaxel-
resistant cells derived from H460 cell line as determined by
both Western blot analysis and immunostaining
3. acute treatment of H460 cells with 10 nM paclitaxel resulted in
induction of annexin IV and conferred ~ fivefold increase in
resistance to paclitaxel
4. transfection of annexin IV cDNA into 293T cells conferred 
threefold increase in resistance to paclitaxel. To our knowl-
edge, this is the first report demonstrating that annexin IV
plays a role in paclitaxel resistance.
Annexin IV belongs to a multigene family of annexins, which
bind to phopholipids in a calcium-dependent manner (Smith and
Moss, 1994). Although the role for each member of the annexin
family is not well understood, annexins seem to be involved in
several cellular processes such as exocytosis, endocytosis and ion
channel activity (Smith and Moss, 1994). Our results suggest that
annexin IV may be one of the proteins to be induced in cells under
stress conditions such as antimitotic drug exposure. Previously
another annexin family member, annexin II, was shown to be over-
expressed in a doxorubicin-resistant small-lung cancer cell line,
H69AR (Cole et al, 1992). However, in our study, annexin II was
not induced in both paclitaxel-resistant H460 cells and H460 cells
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Figure 2 Overexpression of annexin IV in paclitaxel-resistant H460 cells.
(A) Cell extracts from paclitaxel-resistant cell lines were prepared and
analysed on SDS-PAGE then transferred to PVDF membrane. The
membrane was probed with either annexin IV or annexin II antibody. 
(B) Immunostaining using either annexin IV or annexin II was performed in
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Figure 3 Acute treatment of H460 cells with 10 nM paclitaxel upregulates annexin IV. (A) Cell extracts of H460 cells treated with 10nM paclitaxel were
collected up to 4 days. Western blot was performed using either annexin IV or annexin II antibody as described in Figure 2 and Materials and Methods.
(B) Immunostaining of annexin IV in H460 cells treated with or without 10 nM paclitaxel for 1 or 4 days. Arrows indicate the nucleus. (C) H460 cells pretreated
with 10 nM paclitaxel for 4 days were used in IC50 determination of paclitaxel by SRB assay 2 days later. The IC50s of paclitaxel for H460 cells was 5.2 ± 0.5 nM,
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Figure 4 Annexin IV overexpressing clones confer resistance to paclitaxel. (A) Western blot analysis of two vector (293T/Vt#15, 293T/Vt#18) and two annexin
IV (293T/A4#9, 293T/A4#12) clones for annexin IV protein expression. (B) IC50 determination of annexin IV clones by SRB assay. For details see Materials and
Methods
C Btreated with paclitaxel. Thus it is possible that induction of
different classes of annexins by cytotoxic drugs might be cell type-
specific. Alternatively, different cytotoxic drugs may induce indi-
vidual classes of annexin proteins.
How does annexin IV contribute to paclitaxel resistance? We do
not yet know the mechanism by which annexin IV induces pacli-
taxel resistance. It is possible that annexin IV may interact with
other signalling proteins that may influence the paclitaxel-induced
drug resistance. Alternatively, it has been shown that MDR cells
display elevated levels of cytoplasmic calcium (Nygren et al,
1991). Acute paclitaxel treatment increases the calcium level in
H460 cells as determined by using the calcium-binding indicator
Indo-1 AM (data not shown). Previously, an increase in calcium
levels in cells have been shown to induce translocation of annexin
IV in several human cell lines (Sjolin et al, 1994; Mohiti et al,
1995; Barwise and Walker, 1996; Raynal et al, 1996). Thus in
H460 cells or paclitaxel-resistant H460 cells, paclitaxel induced
changes in the intracellular calcium levels and this in turn may
have induced annexin IV expression and its translocation.
Whether the overexpression of annexin IV in H460/T800 cells is
due to amplification of the annexin IV gene is unknown.
Several reports show that paclitaxel resistance is due to a
number of factors besides P-gp. For example, b-tubulin mutation
and alterations have been shown to be associated with paclitaxel
resistance (Ranganathan et al, 1988, 1996, 1998; Haber et al,
1995; Giannakakou et al, 1997; Kavallaris et al, 1997, 1999). We
have shown that a-tubulin also contributes paclitaxel resistance
(Han et al, 1999). Others have shown that caveolin I is up-regu-
lated in paclitaxel-resistant cell lines (Yang et al, 1998). So far we
have examined only annexin II and annexin IV expression in
paclitaxel-resistant cells and we are currently examining other
classes of annexins and the role they may play in drug resistance.
Here we have shown that paclitaxel induces expression of
annexin IV, but not annexin II and annexin IV plays a role in pacli-
taxel resistance. Furthermore, annexin IV alone can confer pacli-
taxel resistance. Therefore, modulation of annexin IV may be a
novel therapeutic target for cells or tumours that have high level of
annexin IV.
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